GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

A number of other equities analysts have also recently issued reports on GRFS. Barclays started coverage on shares of GRIFOLS S A/S in a research report on Friday, June 1st. They set an “overweight” rating for the company. JPMorgan Chase & Co. cut shares of GRIFOLS S A/S from an “overweight” rating to a “neutral” rating in a research report on Wednesday, June 13th. Finally, Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Friday, June 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. GRIFOLS S A/S currently has a consensus rating of “Hold” and an average price target of $22.50.

GRFS stock opened at $21.03 on Wednesday. The company has a market cap of $13.70 billion, a P/E ratio of 19.12, a P/E/G ratio of 1.40 and a beta of 1.19. GRIFOLS S A/S has a 1 year low of $19.84 and a 1 year high of $25.18. The company has a quick ratio of 1.12, a current ratio of 2.90 and a debt-to-equity ratio of 1.52.

GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings data on Friday, July 27th. The biotechnology company reported $0.34 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.34. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.35 billion. GRIFOLS S A/S had a net margin of 16.55% and a return on equity of 17.78%. research analysts expect that GRIFOLS S A/S will post 1.21 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. increased its position in GRIFOLS S A/S by 14.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 20,428 shares of the biotechnology company’s stock valued at $433,000 after acquiring an additional 2,656 shares during the period. First Republic Investment Management Inc. increased its position in GRIFOLS S A/S by 35.0% in the 1st quarter. First Republic Investment Management Inc. now owns 12,892 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 3,340 shares during the period. Blair William & Co. IL increased its position in GRIFOLS S A/S by 9.9% in the 1st quarter. Blair William & Co. IL now owns 38,960 shares of the biotechnology company’s stock valued at $826,000 after acquiring an additional 3,499 shares during the period. Verition Fund Management LLC increased its position in GRIFOLS S A/S by 23.2% in the 2nd quarter. Verition Fund Management LLC now owns 18,818 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 3,539 shares during the period. Finally, US Bancorp DE increased its position in GRIFOLS S A/S by 2.2% in the 1st quarter. US Bancorp DE now owns 179,949 shares of the biotechnology company’s stock valued at $3,815,000 after acquiring an additional 3,893 shares during the period. Institutional investors and hedge funds own 21.05% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Read More: How to Use the New Google Finance Tool

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.